AMLM22/D4: The International AML Platform Consortium (IAPC) trial – is a randomised, 2-arm trial that will investigate the efficacy of oral Azacitidine combined with an allogeneic dendritic cell vaccine vididencel, compared with oral Azacitidine alone, in maintaining or inducing negativity for measurable residual disease (MRD) in AML patients in first complete remission (CR1) following intensive chemotherapy.

Start Date30 Jun 2025

Sponsor / Collaborator

The Australian Leukaemia & Lymphoma Group

[+1]

NCT06454409 / Not yet recruitingPhase 1IIT

A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This phase Ib trial tests the safety, side effects, best dose and effectiveness of regorafenib in combination with venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Regorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps to slow or stop the spread of cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Giving regorafenib in combination with venetoclax and azacitidine may be safe, tolerable and/or effective in treating patients with relapsed or refractory AML.

Start Date20 Mar 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06317649 / RecruitingPhase 2IIT

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Start Date03 Mar 2025

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Azacitidine

100 Translational Medicine associated with Azacitidine

100 Patents (Medical) associated with Azacitidine

5,907

Literatures (Medical) associated with Azacitidine

05 Jul 2106·Oncotarget

Luminal STAT5 mediates H2AX promoter activity in distinct population of basal mammary epithelial cells

Article

Author: Barash, Itamar ; Reichenstein, Moshe ; Kisliouk, Tatiana ; Kfir, Shenhav ; Rauner, Gat

Deregulated STAT5 activity in the mammary gland causes parity-dependent tumorigenesis. Epithelial cell cultures transfected with constitutively active STAT5 express higher levels of the histone H2AX than their non-transfected counterparts. Higher H2AX expression may be involved in tumorigenesis. Here, we aimed to link high STAT5 activity to H2AX-GFP expression by looking for distinct types of mammary cells that express these proteins. In vitro and in transgenic mice, only 0.2 and 0.02%, respectively, of the cells expressed the H2AX-GFP hybrid gene. Its expression correlated with that of the endogenous H2AX gene, suggesting that detectable H2AX-GFP expression marks high levels of H2AX transcript. Methylation of the H2AX promoter characterized non-GFP-expressing H2AX-GFP cells and was inversely correlated with promoter activity. Administration of 5-azacytidine increased H2AX promoter activity in an activated STAT5-dependent manner. In transgenic mice, H2AX-GFP expression peaked at pregnancy. The number of H2AX-GFP-expressing cells and GFP expression decreased in a Stat5a-null background and increased in mice expressing the hyperactivated STAT5. Importantly, H2AX-GFP activity was allocated to basal mammary cells lacking stem-cell properties, whereas STAT5 hyperactivity was detected in the adjacent luminal cells. Knockdown of RANKL by siRNA suggested its involvement in signaling between the two layers. These results suggest paracrine activation of H2AX via promoter demethylation in specific populations of basal mammary cells that is induced by a signal from neighboring luminal cells with hyper STAT5 activity. This pathway provides an alternative route for the luminally confined STAT5 to affect basal mammary cell activity.

31 Dec 2024·Hematology (Amsterdam, Netherlands)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

Article

Author: Yan, Qiong ; Cui, Jingying ; Yuan, Guolin ; Chen, Xuexing ; Li, Chunfang

OBJECTIVES:

The combination of Venetoclax (VEN) and Azacitidine (AZA) increases survival outcomes and yields excellent responses in patients with acute myeloid leukemia (AML). However, dose reduction (or discontinuation) is commonly encountered due to therapy-related toxicity. Thus, this study aimed to investigate the efficiency and safety of a lower dosage of venetoclax for the treatment of AML.

METHODS:

This observational study analyzed the characteristics and outcomes of newly diagnosed AML patients who received 100 mg VEN combined with AZA for 14 days at our institution.

RESULTS:

A total of 36 patients were enrolled, and the median age at diagnosis was 64 years. After a median follow-up of 15 (range 4-29) months, the median overall survival (OS) and progression-free survival (PFS) for the whole cohort were 17 (4-29) months and 12 (1-28) months, respectively. Meanwhile, the overall response rate (ORR) was 69.4%, and the CRc rate was 66.7% in the whole cohort. Subgroup analysis revealed that NPM1 mutations and FAB-M5 subtype were associated with higher response rates, whereas the adverse ELN risk group was predictive of an inferior response. Moreover, ASXL1, NPM1, and IDH1/2 mutations negatively impacted PFS.

DISCUSSION:

Our study optimized the administration of venetoclax plus azacytidine for the treatment of AML patients. Response rates were favorable, with median survival in agreement with the findings of earlier reports, offering valuable insights for optimizing VEN-based regimens.

CONCLUSION:

In summary, the VEN combination regimen is effective for the treatment of newly diagnosed AML patients in the real world despite VEN dose reductions .

31 Dec 2024·Hematology (Amsterdam, Netherlands)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia

Review

Author: Chen, Lin ; Wei, Xudong ; Mi, Ruihua ; Wang, Lin ; Cui, Yu ; Li, Dongbei

OBJECTIVES:

Acute undifferentiated leukemia (AUL) is a clinical rare leukemia with an overall poor prognosis. Currently, there are no well-established treatment guidelines for AUL, further exploration of optimal treatment options is now required.

METHODS:

We report an AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital and we present the clinical features. In addition, we conducted a literature review.

RESULTS:

The "VA" scheme combines agents Venetoclax and Azacitidine that have synergistic therapeutic effect with a tolerable safety profile. There is no previous report of the "VA" scheme employed in AUL treatment. An AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital. The "VA" scheme was administrated, and complete remission (CR) was achieved at the end of the first cycle. The patient then underwent HLA-identical sibling allogeneic hematopoietic stem cell transplantation.

DISCUSSION:

The "VA" scheme has been extensively used in AML treatment, but its application in AUL treatment has not yet been reported. This study is the first to report an AUL patient treated with the "VA" scheme and achieved CR. Our result preliminarily suggested the effectiveness and safety of the "VA" scheme in AUL treatment, but validation is required in more clinical samples. The "VA" scheme provides a new treatment option for AUL patients and deserves further clinical promotion.

546

News (Medical) associated with Azacitidine

12 Jul 2024

·www.drugs.com

Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target are Prostate Cancer Patients Resistant to Hormone Therapy

SEOUL, South Korea, July 11, 2024. ADM Korea, a subsidiary of Hyundai Bioscience, announced on the 8th that the first clinical trial target population for its niclosamide-based oral metabolic anticancer drug will be 'prostate cancer patients resistant to hormone therapy.' Metabolic anticancer drugs regulate the metabolic pathways of cancer cells to induce their death. The niclosamide-based metabolic anticancer drug not only regulates the metabolic pathways of cancer cells to induce their death but also blocks the signaling pathways of cancer cells that avoid anticancer effects, thus inhibiting drug resistance. Currently used anticancer drugs, including hormone therapies, chemotherapies, targeted therapies, and immunotherapies, all fail to resolve the issue of cancer cell drug resistance that arises with long-term treatment. Cancer cell resistance refers to the phenomenon where cancer cells activate cell signaling pathways that help them evade the effects of anticancer agents through repeated drug administration, thereby decreasing the efficacy of the drugs. The biggest challenge in anti-cancer treatment is solving the problem of cancer cell drug resistance, but no drug has yet been developed to address this. Niclosamide is a drug that has been identified to inhibit the Wnt/β-catenin and STAT3 cell signaling pathways, which are activated when cancer cells develop resistance to anticancer drugs, thereby suppressing cancer cell drug resistance. Numerous studies have shown that when niclosamide is used in combination with chemotherapies (such as SN38 and azacitidine), immunotherapies (PD-L1 Ab), targeted therapies (erlotinib), and hormone therapies (enzalutamide), the anticancer effects are superior to those of single-agent treatments. However, due to the longstanding issues of low absorption and short half-life, niclosamide has not been repurposed as an anticancer drug over the past 60 years. CNPharm, which plans to enter into an exclusive license agreement with ADM Korea, has overcome these two issues with its patented technology, successfully repurposing niclosamide as an oral metabolic anticancer drug. In a triple-negative breast cancer model animal study conducted by CNPharm, the combination treatment of the chemotherapeutic agent docetaxel and the niclosamide-based metabolic anticancer drug showed 67% greater anticancer effects compared to the docetaxel-only treatment group. Additionally, in a three-month animal toxicity study of the oral niclosamide-based metabolic anticancer drug, the blood concentration at the NOAEL (No Observable Adverse Effect Level) of niclosamide was 7,888 ng/mL, and cancer cell proliferation was found to be reduced by 50% at a concentration of less than one-tenth of NOAEL level (65~654 ng/mL) in in vitro study, confirming the drug's safety. The niclosamide-based drug is an oral medication offering convenience and ease of administration. ADM Korea plans to conduct clinical trials combining existing treatments with the oral niclosamide-based metabolic anticancer drug for all terminal cancer patients who have developed resistance to existing anticancer drugs. Initially, in August, ADM Korea will submit an IND to the Ministry of Food and Drug Safety of the Republic of Korea for a clinical study combining hormone therapy and the niclosamide-based metabolic anticancer drug in prostate cancer patients resistant to hormone therapy. ADM Korea received a proposal for this combination therapy clinical study from a domestic prostate cancer expert in mid-May. ADM Korea decided to conduct the clinical trial on prostate cancer patients first, as the number of prostate cancer patients is steadily increasing, there is no suitable treatment for patients resistant to hormone therapy, the clinical trial period for prostate cancer is relatively shorter (taking about four weeks), and higher therapeutic effects compared to other cancers can be expected. According to a recent paper published in the Lancet, the number of prostate cancer patients worldwide is expected to more than double from 1.4 million in 2020 to 2.9 million in 2040. The global prostate cancer market is predicted to reach approximately 29.8 trillion KRW by 2025. Combining niclosamide with existing anticancer treatments is expected to solve the problem of drug resistance, significantly enhancing the effectiveness of anticancer therapy compared to single-agent treatments, and drastically improving the quality of life for cancer patients. Vice President of ADM Korea Jin Geun-woo said, "The clinical trial is designed to verify the safety and efficacy of combining niclosamide-based metabolic anticancer drug and hormone therapy in prostate cancer patients over four weeks by observing PSA levels. According to Clinical Cancer Research article {20.12 (2014)}, in animal models with tumors resistant to secondary hormone therapies for prostate cancer, enzalutamide alone reduced tumors by only about 5%, while the combination of niclosamide and enzalutamide resulted in a tumor reduction of about 72%. The niclosamide-based metabolic anticancer drug will mark a historic turning point in prostate cancer treatment." About ADM Korea Inc. and Hyundai Bioscience ADM Korea Inc., a subsidiary of Hyundai Bioscience, is a biotechnology company that develops anticancer drugs and also a Clinical Research Organization (CRO) service company in South Korea. ADM Korea Inc. is listed on the KOSDAQ market (symbol: 187660). Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea. SOURCE ADM Korea Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

License out/inClinical StudyClinical Result

11 Jul 2024

·www.prnewswire.com

ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue of drug resistance. SEOUL, South Korea, July 11, 2024 /PRNewswire/ -- ADM Korea, a subsidiary of Hyundai Bioscience, announced on the 8th that the first clinical trial target population for its niclosamide-based oral metabolic anticancer drug will be 'prostate cancer patients resistant to hormone therapy.' Metabolic anticancer drugs regulate the metabolic pathways of cancer cells to induce their death. The niclosamide-based metabolic anticancer drug not only regulates the metabolic pathways of cancer cells to induce their death but also blocks the signaling pathways of cancer cells that avoid anticancer effects, thus inhibiting drug resistance. Currently used anticancer drugs, including hormone therapies, chemotherapies, targeted therapies, and immunotherapies, all fail to resolve the issue of cancer cell drug resistance that arises with long-term treatment. Cancer cell resistance refers to the phenomenon where cancer cells activate cell signaling pathways that help them evade the effects of anticancer agents through repeated drug administration, thereby decreasing the efficacy of the drugs. The biggest challenge in anti-cancer treatment is solving the problem of cancer cell drug resistance, but no drug has yet been developed to address this. Niclosamide is a drug that has been identified to inhibit the Wnt/β-catenin and STAT3 cell signaling pathways, which are activated when cancer cells develop resistance to anticancer drugs, thereby suppressing cancer cell drug resistance. Numerous studies have shown that when niclosamide is used in combination with chemotherapies (such as SN38 and azacitidine), immunotherapies (PD-L1 Ab), targeted therapies (erlotinib), and hormone therapies (enzalutamide), the anticancer effects are superior to those of single-agent treatments. However, due to the longstanding issues of low absorption and short half-life, niclosamide has not been repurposed as an anticancer drug over the past 60 years. CNPharm, which plans to enter into an exclusive license agreement with ADM Korea, has overcome these two issues with its patented technology, successfully repurposing niclosamide as an oral metabolic anticancer drug. In a triple-negative breast cancer model animal study conducted by CNPharm, the combination treatment of the chemotherapeutic agent docetaxel and the niclosamide-based metabolic anticancer drug showed 67% greater anticancer effects compared to the docetaxel-only treatment group. Additionally, in a three-month animal toxicity study of the oral niclosamide-based metabolic anticancer drug, the blood concentration at the NOAEL (No Observable Adverse Effect Level) of niclosamide was 7,888 ng/mL, and cancer cell proliferation was found to be reduced by 50% at a concentration of less than one-tenth of NOAEL level (65~654 ng/mL) in in vitro study, confirming the drug's safety. The niclosamide-based drug is an oral medication offering convenience and ease of administration. ADM Korea plans to conduct clinical trials combining existing treatments with the oral niclosamide-based metabolic anticancer drug for all terminal cancer patients who have developed resistance to existing anticancer drugs. Initially, in August, ADM Korea will submit an IND to the Ministry of Food and Drug Safety of the Republic of Korea for a clinical study combining hormone therapy and the niclosamide-based metabolic anticancer drug in prostate cancer patients resistant to hormone therapy. ADM Korea received a proposal for this combination therapy clinical study from a domestic prostate cancer expert in mid-May. ADM Korea decided to conduct the clinical trial on prostate cancer patients first, as the number of prostate cancer patients is steadily increasing, there is no suitable treatment for patients resistant to hormone therapy, the clinical trial period for prostate cancer is relatively shorter (taking about four weeks), and higher therapeutic effects compared to other cancers can be expected. According to a recent paper published in the Lancet, the number of prostate cancer patients worldwide is expected to more than double from 1.4 million in 2020 to 2.9 million in 2040. The global prostate cancer market is predicted to reach approximately 29.8 trillion KRW by 2025. Combining niclosamide with existing anticancer treatments is expected to solve the problem of drug resistance, significantly enhancing the effectiveness of anticancer therapy compared to single-agent treatments, and drastically improving the quality of life for cancer patients. Vice President of ADM Korea Jin Geun-woo said, "The clinical trial is designed to verify the safety and efficacy of combining niclosamide-based metabolic anticancer drug and hormone therapy in prostate cancer patients over four weeks by observing PSA levels. According to Clinical Cancer Research article {20.12 (2014)}, in animal models with tumors resistant to secondary hormone therapies for prostate cancer, enzalutamide alone reduced tumors by only about 5%, while the combination of niclosamide and enzalutamide resulted in a tumor reduction of about 72%. The niclosamide-based metabolic anticancer drug will mark a historic turning point in prostate cancer treatment." About ADM Korea Inc. and Hyundai Bioscience ADM Korea Inc., a subsidiary of Hyundai Bioscience, is a biotechnology company that develops anticancer drugs and also a Clinical Research Organization (CRO) service company in South Korea. ADM Korea Inc. is listed on the KOSDAQ market (symbol: 187660). Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea. For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]). SOURCE ADM Korea

License out/inClinical Study

11 Jul 2024

·firstwordpharma.com

Salarius blood cancer study on partial hold in wake of serious adverse event

Shares of Salarius Pharmaceuticals plunged by as much as 26% on Thursday following the company's disclosure of a partial clinical hold imposed by the FDA on its lead drug candidate seclidemstat (SP-2577), an oral LSD1 inhibitor in early testing for both haematological and solid tumours.In a US regulatory filing Thursday, the company said researchers at MD Anderson Cancer Center (MDACC) notified them of a "serious and unexpected Grade 4 adverse event" in a patient participating in MDACC's sponsored trial. The study is evaluating seclidemstat in combination with azacitidine for adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML).No new patients may be enrolled in the study during the partial hold, although currently enrolled subjects who are benefiting from the treatment may continue with the study procedures.Salarius said it will support MDACC researchers in analysing the available data and responding to questions submitted by the FDA. It did not provide details on the nature of the Grade 4 adverse event, which typically refers to life-threatening or disabling side effects according to the National Cancer Institute's classification.Recent EHA readoutThe setback comes just weeks after Salarius presented data on seclidemstat at the European Hematology Association (EHA) annual meeting. The Phase I/II dose-escalation study reported a 43% overall response rate among 14 predominantly higher-risk MDS and CMML patients who had previously failed or relapsed after hypomethylating agent therapy. Median overall survival was 18.5 months, with median event-free survival of 7.2 months.At the time, board chair William McVicar said "we are encouraged by these promising results at this early stage of the study when seclidemstat is combined with azacitidine at doses below what we believe will be the recommended Phase II dose."Seclidemstat is also being investigated in a Phase I/II company-sponsored study in Ewing sarcoma.

Clinical ResultPhase 2

100 Deals associated with Azacitidine

External Link

KEGG	Wiki	ATC	Drug Bank
D03021	Azacitidine	L01BC07	DB00928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Juvenile Myelomonocytic Leukemia	US	Bristol Myers Squibb Co.	20 May 2022
Philadelphia chromosome positive chronic myelogenous leukemia	CN	Celgene Europe Ltd.	24 Apr 2017
High Risk Myelodysplastic Syndrome	AU	Celgene Pty Ltd.	30 Nov 2009
Acute Myeloid Leukemia	EU	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Acute Myeloid Leukemia	IS	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Acute Myeloid Leukemia	LI	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Acute Myeloid Leukemia	NO	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Chronic Myelomonocytic Leukemia	EU	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Chronic Myelomonocytic Leukemia	IS	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Chronic Myelomonocytic Leukemia	LI	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Chronic Myelomonocytic Leukemia	NO	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myeloproliferative Disorders	EU	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myeloproliferative Disorders	IS	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myeloproliferative Disorders	LI	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myeloproliferative Disorders	NO	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myelodysplastic Syndromes	US	Bristol Myers Squibb Co.	19 May 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immunoblastic Lymphadenopathy	Phase 3	JP	Celgene Corp.	06 Nov 2018
Thrombocytopenia	Phase 3	US	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	AU	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	BE	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	BR	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	CA	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	CZ	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	DK	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	FI	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	FR	Celgene Corp.	26 Apr 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03703375 (CTgov)	Phase 3	Immunoblastic Lymphadenopathy	93	Azacitidine (Oral Azacitidine)	ngkitlfads(fbtctwueco) = fwfirourni kvaxkmlogo (jlmivfclss, wbattocczj - rdvqsoonhj) View more	-	08 Jul 2024
NCT03703375 (CTgov)	Phase 3	Immunoblastic Lymphadenopathy	93	Romidepsin+Bendamustine+Gemcitabine (Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine))	ngkitlfads(fbtctwueco) = gimcbfjsvw kvaxkmlogo (jlmivfclss, sxfqomvupi - sfwjuhrmoa) View more	-	08 Jul 2024
NCT04493138 (Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN, Pubmed)	Phase 1	Myeloproliferative Disorders FLT3 \| CBL	12	Azacitidine + Quizartinib 30mg	akwfpmyiaf(ikpykzihgg) = n=4, 33 % opffkeqgsb (iljfzeplit ) View more	Positive	01 Jul 2024
	Phase 1	Myeloproliferative Disorders FLT3 \| CBL	12	Azacitidine + Quizartinib 40mg		Positive	01 Jul 2024
NCT02828358 (AALL15P1, Pubmed)	Phase 2	DNA hypermethylation	31	Azacitidine	itjrjdvgyw(hcartlchgp) = cnpqtevmve aexwnjhynv (bejncqrhhq )	Negative	13 Jun 2024
NCT01757535 (QUAZAR AML-001, ASCO2024) Manual	Phase 3	Acute Myeloid Leukemia with Myelodysplasia-Related Changes Maintenance	101	Oral-AZA 300 mg	cwgtfocnje(swtaqgcaxy) = gggjtlwbgk ehceivyifs (fcjtfsmytv, 14.59-31.97) View more	Positive	24 May 2024
NCT01757535 (QUAZAR AML-001, ASCO2024) Manual	Phase 3		101	Placebo	cwgtfocnje(swtaqgcaxy) = rmbxyujdqq ehceivyifs (fcjtfsmytv, 10.05-19.65) View more	Positive	24 May 2024
NCT05469737 (ASTREON, ASCO2024) Manual	Phase 2	Myelodysplastic Syndromes	47	Oral-AZA 200 mg	kgtwunzkgt(ctpcoxovrw) = ubpkvexzid chbcusysvs (bxvtxkbrvu ) View more	Positive	24 May 2024
NCT05469737 (ASTREON, ASCO2024) Manual	Phase 2	Myelodysplastic Syndromes	47	Oral-AZA 300 mg	kgtwunzkgt(ctpcoxovrw) = lszgyzjiuo chbcusysvs (bxvtxkbrvu ) View more	Positive	24 May 2024
NCT01995578 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	32	low dose 5'-azacitidine	rqpdszdxeb(zmlfivlaxx) = gcgegmwjdd clsmicaqpf (rfwtyugysi, iadrrgzdui - xnajmqtfsr) View more	-	22 May 2024
NCT04722601 (CTgov)	Phase 1/2	Follicular Lymphoma	2	Venetoclax+Obinutuzumab+CC-486	agbgtoblwr(ycmslfevzk) = yyybudbovn uzzvkomzjg (bbbiwmuzzk, ldobrujifp - qpaorecehd) View more	-	16 May 2024
NCT04734990 (EHA2024) Manual	Phase 1/2	Chronic Myelomonocytic Leukemia \| Myelodysplastic Syndromes	14	Seclidemstat+azacitidine	fksalarkug(sdbgezcakw) = gpxzalgxom rtggvsufsk (pywpvfxcyl ) View more	Positive	14 May 2024
EHA2024	Not Applicable	AML1-ETO fusion gene \| MLL-AF9 fusion gene \| MLL-ENL fusion gene	17	Azacitidine maintenance therapy	zwzctfwsbx(dypexqukdm) = piywskuvia ttjnkhxhzu (agbkxesgil ) View more	Positive	14 May 2024
EHA2024	Phase 1/2	CD123 Positive Acute Myeloid Leukemia CD123-positive	-	Pivekimab sunirine (PVEK)	vncabgugkk(yqtfgartgq) = blnrhsipya izsaeecdkm (lofxaimndx )	-	14 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis